Welcome to our dedicated page for Liminatus Pharma SEC filings (Ticker: LIMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liminatus Pharma, Inc. (NASDAQ: LIMN) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Form 8‑K reports on material events. Liminatus is described in public documents as a clinical-stage and preclinical-stage biopharmaceutical and immuno-oncology company focused on targeted cancer therapies, with its common stock and warrants listed on The Nasdaq Stock Market LLC under the symbols "LIMN" and "LIMNW," respectively.
Recent 8‑K filings detail important listing and compliance matters. An August 22, 2025 Form 8‑K reports that Nasdaq notified Liminatus of non-compliance with Listing Rule 5250(c)(1) due to a delayed Quarterly Report on Form 10‑Q for the period ended June 30, 2025. The filing notes that this deficiency letter had no immediate effect on the listing of the company’s common stock and outlines the time frame granted to submit a compliance plan. A November 19, 2025 Form 8‑K discloses additional Nasdaq notices regarding non-compliance with Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C), tied to market value requirements for listed securities and publicly held shares, while stating that LIMN shares continued to trade on Nasdaq and describing the compliance periods and potential options.
Through this page, users can review how Liminatus reports material developments related to its Nasdaq listing status, capital structure, and governance. Alongside 8‑K reports, investors may consult Liminatus’s periodic filings such as Forms 10‑K and 10‑Q, when available, for information on its oncology research programs, risk factors, and financial condition. AI-powered summaries on Stock Titan help explain the key points in lengthy filings, highlight listing compliance disclosures, and make it easier to identify items such as potential financing arrangements, emerging growth company status, and other regulatory details relevant to LIMN.
Liminatus Pharma, Inc. completed a business combination that recapitalized Iris into the combined company, resulting in 26,014,633 shares outstanding at June 30, 2025 compared with 17,500,000 at year-end 2024. The transaction included a $15.0M PIPE, of which $10.56M was cash proceeds and $4.44M converted from related‑party debt into equity. Numerous short‑term related‑party and third‑party loans totaling millions were converted into common stock at closing.
The company treated the deal as a reverse acquisition for accounting under ASC 805, with Iris assets stated at fair value and no goodwill recorded. As of June 30, 2025 management disclosed substantial doubt about the company’s ability to continue as a going concern within one year. Other notable items include deferred underwriting liability of approximately $7.8M for unissued shares, classification of warrants with 6,900,000 public warrants as equity and 835,555 private warrants as liabilities, a $5.0M R&D advance, and $75,000 CEO compensation expense recorded in each six‑month period.
Liminatus Pharma, Inc. reported that on August 22, 2025 it received a notice from the Nasdaq Listing Qualifications Department stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has delayed filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025.
The letter does not immediately affect the listing of the company’s common stock, which continues to trade on Nasdaq under the symbol LIMN. Liminatus Pharma has 60 calendar days, until October 21, 2025, to submit a plan to regain compliance; if Nasdaq accepts the plan, it may grant up to 180 calendar days from the original due date, until February 16, 2026, for the company to file the Form 10-Q and cure the deficiency.
The company states it is in the process of completing the Form 10-Q and intends to file it as soon as practicable. It also issued a press release on August 25, 2025 announcing receipt of the non-compliance notice.
Liminatus Pharma, Inc. (LIMN) Form 3 shows an initial statement of beneficial ownership filed for Iris Acquisition Holdings LLC in connection with an event dated 04/30/2025. The reporting entity lists a total of 6,900,000 shares of Common Stock beneficially owned in a direct ownership form. The filing identifies the reporting person as related to the issuer with the label string that includes Director. The document is signed by Sumit Mehta, Authorized Representative with a signature date of 08/15/2025. No derivative securities are reported and no exercise or conversion terms are listed.